InMed Pharmaceuticals (INM) executive compensation, 2025 proxy

Eric A. Adams, President, Chief Executive Officer and Director, was paid $396,973 in 2025, down 4% from $415,400 the year before.

Filed
November 3, 2025
Annual meeting
December 17, 2025
Pay year
2025
Named executives
4
CEO total pay
$396,973-4% vs prior year
CFO total compensation
$303,7202025 fiscal year
COO total compensation
$347,1232025 fiscal year
SVP total compensation
$323,6232025 fiscal year
CEO option awards
$19,8442025 grant-date fair value
CEO base salary
C$412,000Effective July 1, 2024
CFO appointment
February 20, 2024Netta Jagpal became CFO

How Adams was paid

$396,973 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary76%Bonus19%Option awards5%

Named executive officers

ExecutiveTotal
Eric A. AdamsPresident, Chief Executive Officer and Director$396,973
Netta JagpalChief Financial Officer$303,720
Michael WoudenbergChief Operating Officer$347,123
Eric HsuSenior Vice President, Preclinical Research & Development$323,623

What changed and why

  • $397K$396,973 CEO total compensation in 2025 declined from $415,400 in 2024.
  • $302K$301,630 CEO salary represented the largest component of 2025 compensation.
  • $19,844$19,844 in CEO option-based awards was reported for 2025.
  • $304K$303,720 CFO total compensation reflected her first full fiscal year as CFO.
  • $412KC$412,000 was CEO annual base salary effective July 1, 2024.
  • Annual discretionary bonuses remain subject to Board and Compensation Committee approval.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.